title: Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema.
authors.forename: Fernando Marcondes
authors.initials: FM
authors.lastname: Penha
authors.forename: Mauricio
authors.initials: M
authors.lastname: Maia
authors.forename: José Augusto
authors.initials: JA
authors.lastname: Cardillo
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.forename: Lihteh
authors.initials: L
authors.lastname: Wu
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Rodriguez
authors.forename: María H
authors.initials: MH
authors.lastname: Berrocal
authors.forename: Michel Eid
authors.initials: ME
authors.lastname: Farah
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D016022:Case-Control Studies; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000473:pathology; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide